Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171050 · ClinicalTrials.gov registry record · Phase 4
Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT04171050 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 44 participants.
The verdict
NCT04171050, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
Patients will undergo their vaginal reconstructive surgery in the usual manner, but will also be randomly assigned on the day of surgery to either receive the extra injection of numbing medication at the onset of surgery or not. The chances they will be assigned to the additional injection is 50%. Their care in the hospital and after surgery will be the same. They will participate in the study for a total of 6 weeks during which time they will be asked to complete two phone surveys, during which a provider will check in on pain level and pain medication use, and one office visit at 6 weeks. The office visit is part of their routine care and would be a scheduled visit regardless if they participated in the study or not. If they are unable to return to the office for a postoperative visit at 6 weeks, they will be contact by phone instead to obtain information on satisfaction with postoperative care, any complications after surgery, and overall how they are doing after surgery.
Interventions
- DRUG Local anaesthetic
- DRUG Pudendal Nerve Block plus anesthesia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2023-08-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171050
The ClinicalTrials.gov registry entry for NCT04171050 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Local anaesthetic is the first listed.
NCT04171050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04171050 about?
NCT04171050 is a clinical study titled "Pudendal Enhancement of Enhanced Recovery After Surgery (ERAS) for Reconstructive Surgery (PEERS)". Patients will undergo their vaginal reconstructive surgery in the usual manner, but will also be randomly assigned on the day of surgery to either receive the extra injection of numbing medication at the onset of surgery or not. The chances they will be assigned to the additional injection is 50%. T...
What is the current status of trial NCT04171050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2019-11-14. Estimated completion is 2023-08-28.
What interventions are being tested in trial NCT04171050?
The interventions under investigation include: Local anaesthetic (DRUG), Pudendal Nerve Block plus anesthesia (DRUG).
Who is sponsoring clinical trial NCT04171050?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.